Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
about
A Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerSystematic review of ixabepilone for treating metastatic breast cancer.A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine.A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanesA comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report.Acceptance of oral chemotherapy in breast cancer patients - a survey study.Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneA cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in TurkeyA phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsPooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyEfficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving CapecitabinePhase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.Response of cutaneous metastases from breast cancer to capecitabine.Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility StudyClinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer.Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancerDocetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.Epothilones in the treatment of cancer.Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.Chemotherapy Use, Performance Status, and Quality of Life at the End of LifeHormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with opEfficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients.
P2860
Q26752846-EB032A9B-860B-4544-8681-8E28671FB188Q30248627-77735C5A-8678-44B9-ACB3-2A72E8977625Q30390845-2CF72FCE-0C06-48C1-82F8-A998041CB87DQ33378298-E996804E-D2EE-4041-B499-7C4412EB6511Q33382437-9BF89556-7525-44A9-BEC9-AE24FCCA1462Q33394017-820DFF25-7052-4261-BF57-844A3D9ECD2FQ33421880-73A23200-96BB-4567-A969-47E740399844Q33424774-F87CD4F1-B0E6-4C19-B6DE-0BC83BA868A5Q33426722-CF359CF3-EFC7-48EB-843A-37D1DB0F73B1Q33430813-CBFB438D-325B-4F34-9BF1-AAF48F576847Q33530524-4AB2D4FC-DB7B-424E-8F2F-BDC29C8CABF8Q33580239-73FB9927-CDD1-498E-BA9C-E7FB01969A38Q33870472-6925C067-5D8D-48C8-95D9-C89B1FFC0548Q33990883-3C84C756-30C6-4138-A154-6C92F6A24081Q34130479-2BA16274-07F7-4D85-91B3-648C7E7D111EQ34334959-CF6589C5-3A11-4580-BE0B-89E2105D900CQ34458907-CE29537B-2663-4010-8CA8-5F1DDF4F10F2Q34488678-390D8D9E-79B8-4096-8A4D-B281C701EB2DQ34658293-ECA5B098-6254-41B8-862B-93B1331E5570Q34791173-0CD675DD-5B78-4CC0-BEF7-19B48DCBB258Q35175762-D4FC89DC-B48D-46C2-8C42-EB7CE238073AQ35180944-67FAE8D8-98C0-4827-8870-968F5D24E80CQ35180995-A88A1112-6F0A-49DF-B050-A1077C13B290Q35599769-F0C58335-0CEB-4C1E-BC6D-99691C62B0F1Q35776220-E9E443FE-BCFA-45EA-9999-B07D6031CCF1Q35871180-3AC64336-5EA9-4B1D-93DD-D1BA2D2780EFQ35872691-670D9F61-1C82-4DA7-9707-BCD42E0C43D6Q36023919-D3215F25-BF60-4569-959F-E1405D5CBAD8Q36083065-8C63598D-140E-4E2A-A9DD-6D984F7C756FQ36195618-AC7524AF-C43A-40CF-865B-8EE7E85A2383Q36491842-5229EF8E-D3C8-4DE4-B2E4-6BCCAD3B4E2DQ36506987-63302781-D29E-497D-8998-19FC0CCC5416Q36611795-B0209478-B37E-4ABF-99B9-72E29C2CCE0CQ36697132-2BD207D3-0396-48E5-BD29-72C69A0462E3Q36790047-3C2CD7F4-2392-444E-B5A3-89DDE7E83E18Q36836599-ED84C713-B798-4584-9C58-F46B0946EDE1Q36950497-0B910C22-ED5D-400B-8E16-E6D62F0E2F73Q37003825-67956C58-3C1D-4CAF-B018-F1252A2B18F9Q37270388-B78D6432-A180-4299-B413-A8133FC7F9F6Q37341664-BE2FC1DE-CA97-4083-B7F4-30F4721632FA
P2860
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Multicentre, phase II study ev ...... ated metastatic breast cancer.
@en
Multicentre, phase II study ev ...... ated metastatic breast cancer.
@nl
type
label
Multicentre, phase II study ev ...... ated metastatic breast cancer.
@en
Multicentre, phase II study ev ...... ated metastatic breast cancer.
@nl
prefLabel
Multicentre, phase II study ev ...... ated metastatic breast cancer.
@en
Multicentre, phase II study ev ...... ated metastatic breast cancer.
@nl
P2093
P1476
Multicentre, phase II study ev ...... eated metastatic breast cancer
@en
P2093
E Vuillemin
F Montestruc
H Orfeuvre
P Fumoleau
R Largillier
P304
P356
10.1016/J.EJCA.2003.11.007
P50
P577
2004-03-01T00:00:00Z